Clinical Trial Update: UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating autologous expanded natural killer cell therapy in asymptomatic multiple myeloma has completed enrollment and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Autologous Expanded Natural Killer Cell Therapy (autologous expanded natural killer cells)

Snippet

Sponsor: University of Arkansas | Conditions: Asymptomatic Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2017-04-17